Castle Biosciences (CSTL) Invested Capital (2019 - 2026)

Castle Biosciences has reported Invested Capital for 6 years, with the latest figure at $2.9 million in Q2 2026.

• Quarterly Invested Capital rose 50.05% year-over-year to $2.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.0 million (up 44.22% YoY) and the FY2025 annual result came in at $416000.0, up 0.97% from the prior year.
• Invested Capital improved to $2.9 million in Q2 2026 per CSTL's latest filing, from $1.7 million in the prior quarter.
• Over five years, Invested Capital peaked at $20.8 million in Q1 2022 and troughed at $412000.0 in Q4 2024.
• A 4-year average of $4.2 million and a median of $1.7 million in 2026 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2025 and 2026: Invested Capital rose 0.97% in 2025, then jumped 50.05% in 2026.
• Over 4 years, Invested Capital stood at $20.8 million in 2022, then sank by 98.02% to $412000.0 in 2024, then gained by 0.97% to $416000.0 in 2025, then surged by 601.2% to $2.9 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $2.9 million, $1.7 million, and $416000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.